Ivermectin, A Reanalysis of the Data.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Ivermectin for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2022
   Pooled it
2. Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy.Journal of clinical medicine · 2022
   Article
3. Ivermectin and the Integrity of Healthcare Evidence During COVID-19.Frontiers in public health · 2022
   Review

Corrections and comments

• Commented on by
  Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19.2021
• Comment on
  Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.2021

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as